Share

Big Data- who is in charge?

Denis Lacombe

The ECCO 2018 European Cancer Summit will take place on 7-9 September 2018, in Vienna. The meeting will discuss issues affecting access to high quality cancer care for patients across Europe. Attracting policy makers, key opinion leaders and leaders from cancer health care, patient advocacy and stakeholder communities, the Summit will formulate resolutions that will be addressed at the highest political level.

On this occasion, the summit will host a debate session on big data. The session will address the missing responsibilities of bringing big data opportunities to fruition and who is accountable.

Understanding the biology of cancer has become very important to define individualised treatments for patients. At the early stage of treatment development, big data compiles large amounts of information on multiple levels from DNA, proteins, cells, organs, organisms to ecosystems, allowing researchers to produce better predictive models that can help to create more desirable and cost effective treatments. At a later stage of development and in real life, big data may help to refine the role of treatments in the healthcare setting as well as ensuring the monitoring of long-term safety. However, the medical and research fields are faced with different types of data sets, such as for diagnostics, drug development, treatment decisions, groups of patients and long term follow up of individual patients; big data is therefore a generic terminology. Organization of big data sets should depend on objectives, which will ultimately create different types of challenges and solutions.

Dr Denis Lacombe, Director General of EORTC, will present EORTC’s perspective on the role of data driven research. He will question how big data can support and complement clinical trials, and contribute to re-engineering the processes of clinical research.

Friday 7 September, 15:30-17:30, Debate Session, Big Data- who’s in charge?

 

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023